Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
November 30, 2021 12:14 ET
|
Zealand Pharma
Company announcement – No. 73 / 2021 Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S...
Total number of shares and voting rights in Zealand Pharma at November 30, 2021
November 30, 2021 11:00 ET
|
Zealand Pharma
Company announcement – No. 72 / 2021 Total number of shares and voting rights in Zealand Pharma at November 30, 2021 Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021
November 29, 2021 10:30 ET
|
Zealand Pharma
Company announcement – No. 71 / 2021 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021 Copenhagen, DK and Boston, MA, November 29, 2021 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide
November 22, 2021 08:57 ET
|
Zealand Pharma
Company announcement – No. 70 / 2021 Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide Dapiglutide was assessed to be safe and...
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
November 19, 2021 08:30 ET
|
Zealand Pharma
Company announcement – No. 69/ 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, U.S. November 19, 2021 – Zealand...
Zealand Pharma to Participate in Jefferies London Healthcare Conference
November 12, 2021 08:30 ET
|
Zealand Pharma
Company announcement – No. 68 / 2021 Zealand Pharma to Participate in Jefferies London Healthcare Conference Copenhagen, DK and Boston, MA, U.S. November 12, 2021 – Zealand Pharma A/S (Nasdaq:...
Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinical Studies
November 11, 2021 09:00 ET
|
Zealand Pharma
Company announcement – No. 67/ 2021 Interim report for 9M 2021 Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and...
Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism (CHI)
November 05, 2021 07:30 ET
|
Zealand Pharma
Company announcement – No. 66/ 2021 Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with...
Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity
November 04, 2021 09:00 ET
|
Zealand Pharma
Company announcement – No. 65/ 2021 Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity Preclinical data have shown potent...
Zealand Pharma Hosts Conference Call on November 11 at 4 pm CET (10 am ET) to Present Third Quarter Results for 2021
November 04, 2021 04:00 ET
|
Zealand Pharma
Company announcement – No. 64 / 2021 Zealand Pharma Hosts Conference Call on November 11 at 4 pm CET (10 am ET) to Present Third Quarter Results for 2021 Copenhagen, DK and Boston, MA,...